Western Pacific Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Western Pacific Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.67K	Hold	1,000	–	–	﹤0.01%	170
2026 Q1	$3.07K	Hold	1,000	–	–	﹤0.01%	171
2025 Q4	$4.09K	Buy	+1,000	New	+$4.95K	﹤0.01%	159
2025 Q1	–	Sell	-20	Closed	-$135	–	207
2024 Q4	$135	Hold	20	–	–	﹤0.01%	208
2024 Q3	$132	Hold	20	–	–	﹤0.01%	253
2024 Q2	$150	Hold	20	–	–	﹤0.01%	228
2024 Q1	$199	Hold	20	–	–	﹤0.01%	302
2023 Q4	$197	Hold	20	–	–	﹤0.01%	240
2023 Q3	$153	Hold	20	–	–	﹤0.01%	273
2023 Q2	$149	Hold	20	–	–	﹤0.01%	278
2023 Q1	$133	Hold	20	–	–	﹤0.01%	300
2022 Q4	$154	Buy	+20	New	+$196	﹤0.01%	286

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Western Pacific Wealth Management's RXRX Position: Q2 2026 in Review

Western Pacific Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 1,000 shares worth $3.67K. The position accounts for ﹤0.01% of the portfolio, ranked #170.

Western Pacific Wealth Management first reported a position in RXRX in Q4 2022 and has held it in 12 quarters since. The position peaked at $4.09K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Western Pacific Wealth Management held 1,000 shares of Recursion Pharmaceuticals worth $3.67K as of Q2 2026.
Western Pacific Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Western Pacific Wealth Management's portfolio in Q2 2026, its #170 holding.
Western Pacific Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
Western Pacific Wealth Management's Recursion Pharmaceuticals position peaked at $4.09K in Q4 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Western Pacific Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.